Newswise — Croissy-Beaubourg and Montpellier, March 25, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that it has obtained CE marking for its monitoring test of Stelara® (ustekinumab), the 10thbiotherapy monitoring test of Theradiag’s LISA TRACKER range.
Stelara® is fully human monoclonal antibody that targets the cytokines (interleukin) IL-12 and IL-23 proteins. It was approved for use in moderate to severe plaque psoriasis and psoriatic arthritis. Psoriasis is a very common autoimmune disease, affecting two-to-three percent of the world’s population[1]. Ustekinumab is also currently undergoing clinical trial[2] for the treatment of Crohn’s Disease. Sales of Stelara® were $1.3 billion in 2014.
“Theradiag is the only company in the world to offer such a large range of monitoring tests for the treatment of autoimmune and inflammatory diseases. To maintain our leadership on the market, we will develop monitoring kits for all available and future biotherapies in the fields of autoimmune diseases and cancer. The CE marking that we announce today, the 10th in our LISA TRACKER range, is a proof of this commitment” concludes Michel Finance, Chief Executive Officer of Theradiag.
To read more information please click on this link to view the full THERADIAG receives CE marking for its 10th biotherapy monitoring test[1]World Psoriasis Day
[2]Janssen Biotech (Johnson & Johnson) is currently conducting a Phase III study of ustekinumab in Crohn’s disease
RSS